Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-01-23

FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Supplemental Application (Camber Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for lisdexamfetamine dimesylate from Camber Pharmaceuticals, enabling its generic product to be marketed. Lisdexamfe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LISDEXAMFETAMINE DIMESYLATE (Lisdexamfetamine dimesylate)

Snippet

SUPPL AP for LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)